Embed Size (px)
Citation preview
Synovea DOI: A Cost-Effective Solution in Improving Skin Hydration, Barrier Homeostasis & Epidermal Architecture.
Placebo
• Naturally Derived & Safe Starting Materials• Octanoic acid: Found naturally in coconuts, palm oil, breast
milk and goat milk; Used widely in skin care products as an ester (Caprylic/capric triglycerides)
• Isosorbide: Obtained by double dehydration of sorbitol, a bio-feedstock; Used widely in skin and personal care products as-is and as an ether (Dimethyl Isosorbide).
Improves Water & Barrier Homeostasis
Clinically proven to be very effective in providing long-term skin hydration
Improves Epidermal & Dermo-Epidermal
Architecture
Proven by immuno-fluorescence & histology
Significant stimulation of Aquaporin-3, E-Cadherin, Claudins & Desmosomes.
Gene expression profileFull thickness Mattek Epiderm tissue
DNA microarray on human skin explant studies Synovea® DOI stimulates Tight Junction genes & proteins
Placebo Synovea®DOI
Organotypic skin tissue 51 year old female Synovea DOI treatment for 7 days Stained with Toluidine blue in an alkaline solution
Water and barrier homeostasis of the epidermis is essential for the normal function of skin and for normal stratum corneum (SC) hydration.
It is a determinant of skin appearance, mechanical properties, barrier function, and metabolism.
In addition, it is indispensable in maintaining proper water balance of the body.
Sytheon has designed Synovea DOI, a patent-pending compound, to address these key issues.
In addition, Synovea DOI has been found to improve dermo-epidermal architecture (flattened DEJ Undulating structure) as revealed by the ex-vivo study using human skin explants
D+14 D+16 D+18 D+210
5
1015
20
2530
3540
% Hydration as a Function of Time after discontinuation of any product application
2% DOI+ 2% Glycerol
2% DOI
2% Glycerol
Placebo14
Days
Results & Conclusion No product applied after 14 days Skin hydration level on 18th day is superior to continuous 14-day treatment with 2% Glycerol
Dis
con
tinu
atio
n of
use
Synovea DOI: A Cost-Effective Solution in Improving Skin Hydration, Barrier Homeostasis & Epidermal Architecture.
before treatment
after treatment
Skin dryness & roughness (legs)
Synovea® DOI stimulates E-Cadherin gene & protein
DNA microarray & Ex-vivo on human skin explant studies
Gene expression profileDNA microarray: Full thickness Mattek
Epiderm tissue
Ex-Vivo E-Cadherin expression Eye lid skin explant 51 year old female
Placebo SynoveaDOI
Enhancing skin’s natural moisture retention mechanisms by up-regulating AQP3 gene & protein; Clinically proven.
Restoring barrier function by stimulating key tight junction, desmosome & epidermal differentiation genes & proteins.
Shaping the Epidermal architecture by stimulating dermo-epidermal junction proteins
Summary Key benefits
Me
an
Sc
ore
cyberDERM S12-31
Expert Grader Assessment of Tactile Roughness
(Scale: 0 = Norm al— Sm o oth, soft, supple (yielding without wrinkling), resilient to
8 = Severe Roughness— Rough feel, brittle; hard and inflexible upon m anipulation)
8
Treatment = Synovea DOI Lot# P8537
Control = No Treatm ent
6
4
2
0
Day 0 Day 14 Day 17
C h e m i c a l s t r u c t u re
S y n o v e a ® D O I : R = C 7 H 1 5
D i o c t a n o y l I s o s o r b i d e
Molecular Formula: C22H38O6
CAS Number: 64896-70-4INCI: Isosorbide dicaprylateAppearance: LiquidMiscibility: A wide-range of hydrophobic emollient esters & solubilizersPurity: 97% minPatent Status: US 0110117036A1 WO 2011059866A2
Suitable for sensitive skin with high tolerance: No skin irritation & No skin sensitization (HRIPT; 5% and 20% dilution in corn oil); Elegant skin feel
Suitable for vectorizing cosmetic actives
The information given and the recommendations made herein are based on our research and literature search and are believed to be accurate but no guarantee of their accuracy is made. This information is intended to be helpful, but no warranty is expressed or implied as to the results obtained from use in the formulation, procedure or products suggested herein. Neither
is any permission or recommendation to practice any invention covered by patent either expressed or implied.
USA: Sytheon Ltd, 315 Wootton Street, Boonton, NJ 07005Tel: +00(1)-973-988-1075; [email protected]; www.sytheonltd.com
France: Sytheon SARL, 112 rue de Paris, 92100 Boulogne BillancourtTel +33-(0)1.41.10.81.82; [email protected]
